feedback

Course Director

Naiyer Rizvi, MD
Naiyer Rizvi, MD

Columbia University Medical Center
New York, New York

Faculty

Roy H. Decker
Roy H. Decker, MD, PhD

Yale School of Medicine
New Haven, Connecticut

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Oct-31
Expiration Date:2018-Oct-29
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Until recently, limited advances have been seen in the treatment of stage III non–small-cell lung cancer (NSCLC), but there is finally new hope for progress and potential to improve outcomes in these patients. Although patients with locally advanced, unresectable NSCLC can initially respond to standard chemoradiation therapy, the benefits are often short-lived and the majority eventually develop metastatic disease. However, emerging new evidence indicates that immunotherapy may represent an effective option for these patients. What is the rationale for targeting immune-regulatory pathways in the context of multimodal therapy for earlier stages of lung cancer? What have recent clinical trials with the immune checkpoint inhibitors shown about the efficacy and safety of these therapies in locally advanced disease? Which patients with stage III lung cancer are the best candidates for cancer immunotherapy, and how can these agents be integrated with other standard therapies? These and other critical topics are addressed in this engaging educational activity based on a recent live symposium that encompasses cutting-edge science, as well as the practicalities of patient care.

Upon completion of this activity, participants should be better able to:

  • Characterize the role of the immune system in cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced lung cancer in the context of other standard therapies
  • Discuss key clinical trials evaluating immunotherapy as a novel option for locally advanced NSCLC and the treatment strategies being employed in these trials
  • Assess the efficacy and safety of immune checkpoint inhibitor therapy in locally advanced, unresectable (stage III) NSCLC and implications for clinical practice
  • Identify appropriate patients with locally advanced, unresectable NSCLC who may benefit from immunotherapy as part of multimodal therapy for stage III disease

Target Audience

This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, and other professionals involved in the care of patients with lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 31, 2017 - October 30, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Naiyer Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb and Eli Lilly and Company.
Honoraria from AstraZeneca; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Stock Shareholder in ARMO Biosciences; Gritstone Oncology where Dr. Rizvi is a Co-Founder.
Advisory Board for AstraZeneca; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Naiyer Rizvi, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and other immune-based therapies or combinations for lung cancer.

Faculty

Roy H. Decker, MD, PhD
Associate Professor & Vice Chair
Director of Clinical Research
Department of Therapeutic Radiology
Yale School of Medicine
New Haven, Connecticut

Roy H. Decker, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Merck & Co., Inc.
Advisory Board for AstraZeneca; Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc.

Roy H. Decker, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and other immune-based therapies or combinations for lung cancer.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.